期刊簡介預計審稿時間： 較慢,6-12周

OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents

-Novel therapeutic regimens for improved benefit and/or decreased side effects

-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.

-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.

-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.

-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.

-Single nucleotide polymorphism (SNP) studies will not be considered.

OncoTargets and Therapy 是一本國際同行評審期刊，專注于癌癥研究的分子方面，即所有類型癌癥的分子診斷和靶向分子或精準治療。

該期刊的特點是快速報道高質量的原創研究、基礎科學、評論和評估、專家意見和評論，為癌癥或癌癥亞型提供新的見解。

該期刊涵蓋的具體主題包括：

-新的治療靶點和創新藥物

-用于提高療效和/或減少副作用的新型治療方案

-早期臨床試驗

向 OncoTargets and Therapy 投稿時的進一步考慮：

-包含體內動物模型數據的研究將得到優先考慮。

-組織微陣列分析將不予考慮，除非它們得到涉及多個細胞的綜合生物學研究的支持行。

-只有通過全面的體外數據和人體組織樣本分析進行驗證后，才會考慮生物標志物關聯研究。

-利用公開數據（例如 GWAS/TCGA/GEO 等）的研究應增加有關特定疾病或相關表型的知識體系，并且必須使用作者自己的數據通過在獨立樣本集中復制和功能跟蹤進行驗證。

-生物信息學研究必須使用作者自己的數據通過在獨立樣本集中復制和功能跟蹤進行驗證。

-單核苷酸多態性 (SNP) 研究將不予考慮。

《Oncotargets And Therapy》(腫瘤靶點和治療)編輯部通訊方式為PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752。如果您需要協助投稿或潤稿服務，您可以咨詢我們的客服老師。我們專注于期刊咨詢服務十年，熟悉發表政策，可為您提供一對一投稿指導，避免您在投稿時頻繁碰壁，節省您的寶貴時間，有效提升發表機率，確保SCI檢索（檢索不了全額退款）。我們視信譽為生命，多方面確保文章安全保密，在任何情況下都不會泄露您的個人信息或稿件內容。